NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) Receives Average Rating of “Hold” from Analysts

Shares of NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) have received an average recommendation of “Hold” from the five analysts that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. The average 1 year target price among analysts that have covered the stock in the last year is $11.6667.

NMTC has been the subject of several research analyst reports. Wall Street Zen raised NeuroOne Medical Technologies to a “sell” rating in a research note on Saturday, February 21st. JonesTrading initiated coverage on NeuroOne Medical Technologies in a research note on Monday, March 2nd. They issued a “buy” rating and a $9.00 price objective for the company. Zacks Research downgraded NeuroOne Medical Technologies from a “strong-buy” rating to a “hold” rating in a research note on Friday, March 13th. Weiss Ratings downgraded NeuroOne Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, May 11th. Finally, LADENBURG THALM/SH SH raised their price objective on NeuroOne Medical Technologies from $1.60 to $8.00 and gave the company a “buy” rating in a research note on Wednesday, May 13th.

NeuroOne Medical Technologies Trading Down 2.0%

NeuroOne Medical Technologies stock opened at $3.39 on Wednesday. NeuroOne Medical Technologies has a twelve month low of $3.27 and a twelve month high of $6.96. The stock has a 50 day moving average of $4.25 and a two-hundred day moving average of $4.48. The stock has a market capitalization of $29.22 million, a price-to-earnings ratio of -3.99 and a beta of 0.51.

NeuroOne Medical Technologies (NASDAQ:NMTC) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.02). The business had revenue of $2.39 million during the quarter, compared to analyst estimates of $2.58 million. NeuroOne Medical Technologies had a negative net margin of 68.35% and a negative return on equity of 98.33%. Equities analysts predict that NeuroOne Medical Technologies will post -0.35 earnings per share for the current year.

Hedge Funds Weigh In On NeuroOne Medical Technologies

Several hedge funds have recently bought and sold shares of the stock. Legato Capital Management LLC purchased a new position in NeuroOne Medical Technologies during the fourth quarter worth $34,000. Squarepoint Ops LLC purchased a new stake in shares of NeuroOne Medical Technologies in the fourth quarter valued at $36,000. Susquehanna International Group LLP purchased a new stake in shares of NeuroOne Medical Technologies in the third quarter valued at $47,000. XTX Topco Ltd grew its position in shares of NeuroOne Medical Technologies by 321.1% in the fourth quarter. XTX Topco Ltd now owns 85,454 shares of the company’s stock valued at $65,000 after purchasing an additional 65,163 shares during the period. Finally, Renaissance Technologies LLC grew its position in shares of NeuroOne Medical Technologies by 10.2% in the fourth quarter. Renaissance Technologies LLC now owns 763,028 shares of the company’s stock valued at $578,000 after purchasing an additional 70,428 shares during the period. Hedge funds and other institutional investors own 16.07% of the company’s stock.

About NeuroOne Medical Technologies

NeuroOne Medical Technologies Corp. is a medical device company focused on developing advanced neural interface technologies for diagnostic and therapeutic applications in neurosurgery and neurology. The company’s core mission is to improve patient outcomes through next-generation electrode systems that enable high-resolution neural recording and targeted stimulation. By leveraging proprietary thin-film microelectrode arrays, NeuroOne aims to offer clinicians unprecedented single-unit precision during brain mapping procedures.

The company’s flagship platform, the EVO™ system, integrates thin-film neural electrodes with intraoperative monitoring hardware and software.